Hormonal
GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and slow kidney function decline in patients with type 2 diabetes, with benefits extending to those with established chronic kidney disease (CKD).
If you have Type 2 Diabetes and kidney issues or heart disease, GLP-1 medications (like Ozempic, Trulicity, or Victoza) are now considered essential, not just optional. They protect your heart and kidneys beyond just lowering blood sugar. Start with a low dose to avoid stomach upset, and work with your doctor to find the right strength. These are often covered by insurance for kidney/heart protection.
GLP-1 receptor agonists represent an important therapeutic class for the management of type 2 diabetes (T2D), demonstrating benefits beyond glycemic control, including lowering of blood pressure and body weight, and importantly, decreased risk of development of new or worsening chronic kidney disease (CKD) and reduced rates of atherosclerotic cardiovascular events.
Why this rating
Supported by multiple large CVOTs (LEADER, SUSTAIN-6, etc.) and meta-analyses of over 56,000 participants.
Source
Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Radica Z. Alicic et al. · Journal of Clinical Medicine · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →